Welcome to our dedicated page for Labcorp Holdings news (Ticker: LH), a resource for investors and traders seeking the latest updates and insights on Labcorp Holdings stock.
Labcorp Holdings Inc. provides laboratory services spanning diagnostics and drug development laboratory capabilities for doctors, hospitals, pharmaceutical companies, researchers and patients. News about LH commonly covers earnings releases and guidance, dividend declarations, specialty and companion diagnostics, oncology testing, drug-screening products, and collaborations that expand access to advanced laboratory services.
Company updates also address Labcorp's Diagnostics Laboratories and Biopharma Laboratory Services activities, including FDA-cleared or FDA-approved tests, pediatric diagnostics development, real-world data platforms, digital pathology and AI-enabled laboratory operations. Recurring announcements connect Labcorp's national diagnostic infrastructure with health systems, biopharmaceutical customers and technology partners.
Labcorp (NYSE: LH) announced nationwide availability of Agilent's PD-L1 IHC 22C3 pharmDx on April 22, 2026, the only FDA‑approved companion diagnostic to identify patients with platinum‑resistant ovarian cancer eligible for Merck's KEYTRUDA therapies.
Labcorp joined Agilent's Early Validation Program to prepare standardized training and rapid rollout following the FDA's February approvals of KEYTRUDA and KEYTRUDA QLEX alongside the diagnostic.
Labcorp (NYSE: LH) launched the Labcorp Fentanyl Urine Visual Test, the first FDA-cleared rapid fentanyl urine test of its kind manufactured in the United States. The test delivers results in 10 minutes, detects norfentanyl with up to a 48-hour window, and is for CLIA-certified professional use.
Results are intended as preliminary screening and should be confirmed by laboratory methods. The test is available through Labcorp Point of Care (formerly MEDTOX Diagnostics), with product branding transitioning during 2026.
Labcorp (NYSE: LH) launched an AI-powered real-world data platform with AWS and Datavant to speed Alzheimer's research, using deidentified laboratory, genomic and claims data. The platform aims to compress months of data preparation into minutes, completes initial validation in spring 2026, and will expand through 2026 to additional disease areas.
It supports cohort identification, treatment-effectiveness analysis, and trial recruitment using Amazon Bedrock and SageMaker and privacy-preserving connectivity.
Labcorp (NYSE: LH) and Children's Hospital of Philadelphia announced a strategic collaboration on April 13, 2026 to speed discovery, development and national availability of specialized pediatric diagnostics.
The partnership creates a joint pediatric diagnostics innovation pipeline to develop age-appropriate tests across oncology, metabolic disease, autoimmune conditions and rare disorders and to expand nationwide access through Labcorp's laboratory network.
Labcorp (NYSE: LH) announced a quarterly cash dividend of $0.72 per share on April 9, 2026. The dividend is payable on June 11, 2026 to holders of record at the close of business on May 29, 2026.
This returns cash to shareholders and sets clear payment and record dates for investors.
Labcorp (NYSE: LH) will report first-quarter 2026 financial results before the market opens on April 30, 2026. A live webcast will begin at 9:00 a.m. ET the same day to discuss results. The earnings release and financial information will be posted on the investor relations website.
A replay will be posted approximately two hours after the live event and will remain available for one year on the site's News & Events section.
Labcorp (NYSE: LH) and Illumina on March 18, 2026 expanded a collaboration to broaden precision oncology testing access via distributed IVD kits, new CGP and WGS test development, and evidence generation to support payer coverage.
Plans include exploring co-commercialization of FDA-authorized PGDx elio plasma focus Dx and FDA-approved TruSight Oncology Comprehensive, and continuing joint studies (one evaluated >7,600 NSCLC samples, detecting actionable variants in >72%).
Labcorp (NYSE: LH) expanded its collaboration with PathAI to deploy AISight Dx, an FDA-cleared digital pathology platform, across Labcorp's national anatomic pathology labs and hospital collaborations on Feb. 23, 2026. The cloud-based system enables fully digital workflows, AI-powered image analysis, secure storage and connectivity.
According to the company, deployment aims to scale digital slide review, improve turnaround times, enhance collaboration and support Labcorp's precision medicine products, building on a 2019 strategic investment in PathAI and prior AI-driven clinical trial support.
Labcorp (NYSE: LH) reported Q4 2025 revenue of $3.52B and full-year revenue of $13.95B (up 7.2% year-over-year). Full-year adjusted EPS rose to $16.44 (from $14.57), and free cash flow was $1.21B. The company provided 2026 guidance: enterprise revenue $14.61B–$14.79B, adjusted EPS $17.55–$18.25, and free cash flow $1.24B–$1.36B.
Operational highlights include 13 strategic transactions, >130 new tests launched, the first FDA-cleared blood test for Alzheimer’s in primary care, and a planned 500,000 sq ft Central Laboratory investment.
Labcorp (NYSE: LH) announced nationwide availability of the Elecsys® pTau-181 blood test cleared by the FDA to aid initial assessment of Alzheimer’s disease in primary care for symptomatic patients aged 55 and older. The test offers a 97.9% negative predictive value, is performed by simple blood draw at Labcorp's >2,200 patient service centers, and aims to reduce reliance on brain scans or lumbar punctures. Developed by Roche Diagnostics and FDA-cleared in 2025, the test complements Labcorp's biomarker portfolio and supports diagnostic and therapeutic workflows, including contributions to >90 Alzheimer's protocols across 45 countries.